Skip to main content

A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations

Abstract

Background

Ductal adenocarcinoma and neuroendocrine cancer are rare subtypes of prostate cancer with poor prognosis and limited therapeutic options. We present the first case of ductal adenocarcinoma having a neuroendocrine phenotype.

Case presentation

A 63-year-old man presented with gross hematuria and urinary retention, and his serum prostate-specific antigen level was 4.58 ng/mL. We performed transurethral resection of the prostate, and the diagnosis was ductal adenocarcinoma with a Gleason score of 5 + 4 for acinar adenocarcinoma. Magnetic resonance imaging showed local invasion of left lobe of the prostate and bone metastasis of the left trochanteric section of the femur. Multidisciplinary treatments such as androgen deprivation therapy, chemoradiation therapy, and surgery for metastatic lesions have led to long-term survival. Since next-generation sequencing revealed PTEN and RB1 co-loss and TP53 mutations, we re-evaluated the immunohistochemistry and he was found to be positive for synaptophysin.

Conclusions

This is the first Japanese case of ductal adenocarcinoma with a neuroendocrine phenotype. Genetic analysis may help not only guide the therapeutic strategies, but also sometimes with the diagnosis.

Peer Review reports

Background

Ductal adenocarcinoma (DCa) of the prostate is a rare morphologic subtype, occurring in less than 1% and up to 5% in cases of acinar adenocarcinoma (ACa), defined histologically by elongated cells and papillary or cribriform architecture [1,2,3]. Since DCa often presents at an advanced clinical stage with local or distant metastases and no effective treatment has been established, the prostate-specific mortality is significantly worse than that of ACa [1]. In contrast, neuroendocrine prostate cancer (NEPC) is an extremely rare entity with poor prognosis and limited therapeutic options [4]. The pathological characteristics of NEPC include staining with immunohistochemical markers (CD56, synaptophysin, chromogranin A, and NSE), high proliferative rate (Ki67 > 50%), and the presence of TMPRSS2-ERG rearrangement. Synaptophysin is the most sensitive marker, NSE is also sensitive but not specific, and chromogranin A is the most specific marker [5, 6]. Little is known regarding the genetic and specific histopathological characteristics of DCa and NEPC, and to date, few studies have investigated the genetic profile of these tumors. Therefore, the accumulation of case reports and genetic or histopathological analyses is expected to add to our understanding to this disease entity. Herein, we report a case of a DCa mixed with ACa with a neuroendocrine phenotype.

Case presentation

A 63-year-old man presented with gross hematuria and urinary retention. He had no remarkable medical or family history. His serum prostate-specific antigen (PSA) was 4.58 ng/mL, and urine cytology was class 3 (atypical urothelial cells). Since cystoscopy revealed a papillary tumor in the prostatic urethra, we performed transurethral resection of the prostate. The pathological diagnosis was poorly differentiated adenocarcinoma with Gleason score of 5 + 4 = 9 with DCa (Fig. 1). Magnetic resonance imaging showed local invasion of the left lobe of the prostate and bone metastasis of the left trochanteric section of the femur (Fig. 2). Although he was treated with androgen deprivation therapy (ADT), 10 months later, the disease became castration-resistant prostate cancer. At this point, the PSA level was 3.66 ng/mL and serum NSE was 9.6 ng/mL. Then, we administered three courses of docetaxel (75 mg/m2) as the second-line therapy. Since the serum PSA level was decreased to 0.54 ng/mL, the patient was treated with a combination of 160 mg of enzalutamide and intensity-modulated radiation therapy (IMRT) consisting of 78 Gy administered in 39 fractions for the prostate and 40 Gy administered in 14 fractions for the left femur as the third-line therapy, which decreased the PSA level to be nadir of 0.03 ng/mL. After the combination therapy, enzalutamide was continued for 13 months, and when the serum PSA increased to 0.35 ng/mL, four courses of cabazitaxel (25 mg/m2) were administered as the fourth-line therapy. Despite multimodal therapy, positron emission tomography/computed tomography (PET/CT) showed viability of the left trochanteric section of the femur. Thus, we performed left femoral head replacement, and we confirmed the absence of viable cancer cells pathologically. After 1 year, he was treated with local radiation of 60 Gy administered in 25 fractions because the PSA level increased to 0.76 ng/mL and pelvic lymph node metastasis was noted. At this point, we performed targeted genome sequencing of the tumor specimen from the transurethral resection and re-evaluated the immunochemistry findings. We identified PTEN p. R233fs*10, RB1 loss exons 18–27, and TP53 p.R249G mutations by genome sequencing (Table 1), and the patient was found to be positive for synaptophysin by immunohistochemistry (Fig. 1F). Currently, he is undergoing chemotherapy with cabazitaxel, and his PSA/NSE level was around 0.20/9.0 ng/mL.

Fig. 1
figure1

Representative images of A hematoxylin and eosin staining and B PSA, C loss of PTEN, D loss of RB1, E TP53 and F synaptophysin immunohistochemical staining of transurethral resection of prostate specimens. Bar = 0.1 mm

Fig. 2
figure2

Serum PSA and NSE levels and time course for multidisciplinary treatments

Table 1 Results of FoundationOne® companion diagnostic (F1CDx) assay

Discussion and conclusions

Patients with metastatic ACa are currently best treated with palliative drug treatments, such as ADT plus androgen receptor-targeted agents or chemotherapy [7]. Recent studies have demonstrated that early detection and aggressive treatment of metastatic lesions with surgery or radiation therapy appears to be a feasible strategy in patients with newly diagnosed oligometastatic ACa [8,9,10]. On the other hand, DCa has no established treatment strategy, and palliative ADT or chemotherapy alone cannot be expected to have a long-term prognosis even though a significantly greater frequency of men with DCa had local or distant metastasis at diagnosis. In our case, the patient was aggressively treated with ADT and chemotherapy with IMRT and local radiation therapy, while the initial diagnosis was a DCa with a Gleason score of 5 + 4 = 9 of ACa and bone metastasis. When PET/CT revealed revitalization of the left trochanteric section of the femur, we decided to perform the operation and confirmed the absence of viable cancer cells. Based on these aggressive multidisciplinary treatments made for the long-term survival.

Currently, in Japan, we can perform genome sequencing of tumor specimens in order to find the next treatment target drug in rare cancer patients in which the typical treatment effect becomes less remarkable. In this case, we identified PTEN and RB1 co-loss and TP53 mutations by next-generation sequencing. PTEN loss, RB1 loss, and TP53 mutations are common genomic alterations in many cancers. Vinceneux et al. reported that a complete loss of PTEN expression was more frequent in DCa (34%) than in ACa (11%) by immunohistochemistry [11]. Some reports have also indicated that PTEN loss occurring in DCa is associated with multiple markers of poor prognosis and has recently been associated with cribriform morphology, similar to that of ductal histology [12,13,14]. In fact, there were some scattered areas of complete loss of PTEN expression (Fig. 1C). Similarly, loss of function of the tumor suppressive function of TP53 and RB1 are the common mutant genes in ACa and are associated with aggressive tumor progression or metastatic ACa [15,16,17], while there was no confident evidence about the correlation between RB1 or TP53 mutation and DCa. Tarjan et al. reported that the combination of TP53 and chromogranin A expression in cancer cells is associated with ductal differentiation of ACa [18]. On the other hand, we performed immunohistochemistry for chromogranin A and synaptophysin staining, and the patient was found to be positive for synaptophysin (Fig. 1F) because these three genomic mutations are often found in patients with NEPC [19]. These results indicated that we could have the treatment option to perform the administration of a platinum agent for the future.

In conclusion, to the best of our knowledge, there are few case reports of genomic analysis for DCa, which is the first Japanese report of DCa with PTEN and RB1 co-loss and TP53 mutation. Genetic analysis may help not only guide the therapeutic strategies, but also sometimes with the diagnosis.

Availability of data and materials

The datasets used and analyzed in this study are available from the corresponding author on reasonable request.

Abbreviations

DCa:

Ductal adenocarcinoma

ACa:

Acinar adenocarcinoma

NEPC:

Neuroendocrine prostate cancer

PSA:

Prostate-specific antigen

ADT:

Androgen deprivation therapy

IMRT:

Intensity modulated radiation therapy

PET/CT:

Positron emission tomography/ computed tomography

References

  1. 1.

    Morgan TM, Welty CJ, Vakar-Lopez F, Lin DW, Wright JL. Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen. J Urol. 2010;184(6):2303–7.

    CAS  Article  Google Scholar 

  2. 2.

    Meeks JJ, Zhao LC, Cashy J, Kundu S. Incidence and outcomes of ductal carcinoma of the prostate in the USA: analysis of data from the surveillance, epidemiology, and end results program. BJU Int. 2012;109(6):831–4.

    Article  Google Scholar 

  3. 3.

    Seipel AH, Delahunt B, Samaratunga H, Egevad L. Ductal adenocarcinoma of the prostate: histogenesis, biology and clinicopathological features. Pathology. 2016;48(5):398–405.

    Article  Google Scholar 

  4. 4.

    Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera JM, Reuter VE, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014;38(6):756–67.

    Article  Google Scholar 

  5. 5.

    Kranitz N, Szepesvary Z, Kocsis K, Kullmann T. Neuroendocrine cancer of the prostate. Pathol Oncol Res. 2020;26(3):1447–50.

    Article  Google Scholar 

  6. 6.

    Parimi V, Goyal R, Poropatich K, Yang XJ. Neuroendocrine differentiation of prostate cancer: a review. Am J Clin Exp Urol. 2014;2(4):273–85.

    PubMed  PubMed Central  Google Scholar 

  7. 7.

    Cornford P, van den Bergh RCN, Briers E, van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79(2):263–82.

    CAS  Article  Google Scholar 

  8. 8.

    Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol. 2015;193(3):832–8.

    Article  Google Scholar 

  9. 9.

    O’Shaughnessy MJ, McBride SM, Vargas HA, Touijer KA, Morris MJ, Danila DC, et al. A pilot study of a multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer. Urology. 2017;102:164–72.

    Article  Google Scholar 

  10. 10.

    Parikh RR, Byun J, Goyal S, Kim IY. Local therapy improves overall survival in patients with newly diagnosed metastatic prostate cancer. Prostate. 2017;77(6):559–72.

    Article  Google Scholar 

  11. 11.

    Vinceneux A, Bruyere F, Haillot O, Charles T, de la Taille A, Salomon L, et al. Ductal adenocarcinoma of the prostate: clinical and biological profiles. Prostate. 2017;77(12):1242–50.

    CAS  Article  Google Scholar 

  12. 12.

    Gillard M, Lack J, Pontier A, Gandla D, Hatcher D, Sowalsky AG, et al. Integrative genomic analysis of coincident cancer foci implicates CTNNB1 and PTEN alterations in ductal prostate cancer. Eur Urol Focus. 2019;5(3):433–42.

    Article  Google Scholar 

  13. 13.

    Jeong SU, Kekatpure AK, Park JM, Han M, Hwang HS, Jeong HJ, et al. Diverse immunoprofile of ductal adenocarcinoma of the prostate with an emphasis on the prognostic factors. J Pathol Transl Med. 2017;51(5):471–81.

    Article  Google Scholar 

  14. 14.

    Ronen S, Abbott DW, Kravtsov O, Abdelkader A, Xu Y, Banerjee A, et al. PTEN loss and p27 loss differ among morphologic patterns of prostate cancer, including cribriform. Hum Pathol. 2017;65:85–91.

    CAS  Article  Google Scholar 

  15. 15.

    Arora K, Barbieri CE. Molecular subtypes of prostate cancer. Curr Oncol Rep. 2018;20(8):58.

    Article  Google Scholar 

  16. 16.

    Thangavel C, Boopathi E, Liu Y, Haber A, Ertel A, Bhardwaj A, et al. RB loss promotes prostate cancer metastasis. Can Res. 2017;77(4):982–95.

    CAS  Article  Google Scholar 

  17. 17.

    Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355(6320):78–83.

    CAS  Article  Google Scholar 

  18. 18.

    Tarjan M, Lenngren A, Hellberg D, Tot T. Immunohistochemical verification of ductal differentiation in prostate cancer. APMIS. 2012;120(6):510–8.

    Article  Google Scholar 

  19. 19.

    Kaur H, Samarska I, Lu J, Faisal F, Maughan BL, Murali S, et al. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance. Prostate. 2020;80(12):1012–23.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

Yoko Suzuki provided technical assistance.

Funding

None.

Author information

Affiliations

Authors

Contributions

Conception and design: TK, HN, and MO. Acquisition and analysis of data: TK, KN, KS, HH, and HN. Drafting the manuscript and figures: HK, TK, SM, HN, and MO. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Takeo Kosaka.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the Ethical Committee of Keio University Hospital (#20160084).

Consent for publication

Written informed consent was obtained from the patient for publication of this case report. A copy of the consent form is available for review by the Editor of this journal.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kobayashi, H., Kosaka, T., Nakamura, K. et al. A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations. BMC Med Genomics 14, 245 (2021). https://doi.org/10.1186/s12920-021-01093-9

Download citation

Keywords

  • Ductal adenocarcinoma
  • Neuroendocrine prostate cancer
  • Next-generation sequencing
  • Case report